Sarepta still on track for eteplirsen NDA next year, says Piper Jaffray

After Sarepta presented 96-week follow-up data from a study of eteplirsen, Piper Jaffray said its still sees the company as on track to file a new drug application for the drug in the first half of next year. Piper keeps its Overweight rating and $58 target on Sarepta shares.

Advertisement